Company intelligence / Profile preview
Vasomune Therapeutics, Inc.
Toronto, Ontario, Canadavasomune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vasomune’s lead candidate AV‑001 is a first-in-class fully synthetic PEGylated peptide Tie2 agonist. It has demonstrated strong safety and tolerability in Phase 1 trials with no drug-related discontinuations or deaths. The ongoing Phase 2a trial targets moderate-to-severe ARDS in hospitalized patients with pneumonia. Preclinical studies showed improved survival, reduced pulmonary edema, and enhanced lung function compared to controls. The FDA granted Fast Track designation to AV‑001 for this indication in May 2024.[1][5]
- Therapeutic areas
- PulmonologyCardiovascularNephrologyNeurologyInfectious Diseases
- Modalities
- Synthetic peptides (PEGylated peptide)Small molecules (as per some sources)[2][6]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AnGes, Inc. [Tokyo Stock Exchange TYO :4563], co-development partner for AV‑001 globally since early stages of development.[1][4]Sunnybrook Research Institute/Sunnybrook Health Sciences Centre—originator of the technology/licensing partner.[4]US Department of Defense Congressionally Directed Medical Research Programs—major non-dilutive funding support for clinical advancement.[1]National Research Council of Canada Industrial Research Assistance Program—R&D funding support.[1]
Beyond the preview
Go deeper on Vasomune Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasomune Therapeutics, Inc..